Nanology Labs develops the next generation drug delivery nanoparticle platform technology with active BBB crossing capability. Nanology Labs' lead candidate, T-MX2100, is a first-in-class nanoparticle agent designed to modulate tumor environment by overcoming tumor hypoxia (lack of oxygen). The agent generates oxygen molecule in the solid tumor and safely kill cancer cells in combination with other therapies.

Nanology Labs Inc. Logo



Event details

Date: June 10 - 17, 2021

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


30 in total